Raymond James Lowers Danaher (NYSE:DHR) Price Target to $300.00

Danaher (NYSE:DHR) had its price objective lowered by stock analysts at Raymond James from $310.00 to $300.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the conglomerate’s stock. Raymond James’ price target would indicate a potential upside of 21.03% from the company’s current price.

Other equities research analysts have also issued reports about the company. Leerink Partners raised their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group raised their price target on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. TD Cowen boosted their price objective on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Evercore ISI raised their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Robert W. Baird cut their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $287.28.

Danaher Price Performance

NYSE:DHR opened at $247.88 on Wednesday. The business’s 50-day moving average is $270.43 and its 200 day moving average is $260.43. Danaher has a 12 month low of $182.09 and a 12 month high of $281.70. The company has a market capitalization of $183.60 billion, a P/E ratio of 42.03, a P/E/G ratio of 4.49 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the company earned $2.02 EPS. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. On average, equities research analysts forecast that Danaher will post 7.59 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Danaher

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tsfg LLC raised its position in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Danaher during the second quarter worth $25,000. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher during the second quarter valued at $25,000. Redmont Wealth Advisors LLC acquired a new position in shares of Danaher in the 1st quarter valued at $30,000. Finally, MFA Wealth Advisors LLC purchased a new position in Danaher in the 2nd quarter worth $51,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.